SKYEHealthcare · BiotechnologyThe 5 Wall Street analysts covering Skye Bioscience, Inc. hold a median 12-month price target of $4 — +1328.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Skye Bioscience, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (93): Smaller than most of the companies we track.
Momentum (4): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SKYE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +1328.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Sept 2025 | HC Wainwright & Co. | Initiates | Buy | $20 |
| 15 Aug 2025 | Evercore ISI Group | Initiates | Outperform | — |
| 24 June 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 21 Mar 2025 | Citizens Capital Markets | Reiterates | Market Outperform | — |
| 21 Mar 2025 | Craig-Hallum | Maintains | Buy | — |
| 28 Feb 2025 | William Blair | Initiates | Outperform | — |
| 30 Sept 2024 | Scotiabank | Initiates | Sector Outperform | — |
| 20 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 20 Sept 2024 | Piper Sandler | Reiterates | Overweight | — |
| 10 Sept 2024 | JMP Securities | Initiates | Market Outperform | — |
| 9 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 6 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 27 Aug 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 9 July 2024 | Craig-Hallum | Initiates | Buy | — |
| 1 July 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 18 June 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 17 June 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 23 May 2024 | Cantor Fitzgerald | Initiates | Overweight | — |
| 12 Apr 2024 | Oppenheimer | Initiates | Outperform | — |
| 14 Mar 2024 | Piper Sandler | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SKYE appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 68% of US stocks
Cheaper than 86% of US stocks
Cheaper than 61% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 6% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Skye Bioscience, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Skye Bioscience, Inc. (SKYE) held an M&A call, and Seeking Alpha published the prepared remarks transcript from the event.
Why it matters — SKYE watchers would care because the M&A call transcript provides direct insight into the company's strategic rationale behind its merger and acquisition activities.
Skye Bioscience and privately-held Redx Pharma announced a definitive transaction agreement to combine, with the combined company to trade on Nasdaq as Fibrx Therapeutics, led by Redx's management team and board. A syndicate of institutional investors committed approximately $125 million in aggregate financings, expected to fund operations through the lead program RXC008's Phase 2 clinical trial, with topline data expected in H2 2028.
Why it matters — SKYE watchers would care because the transaction substantially changes the company's identity and pipeline, refocusing it as a fibrosis-focused firm under Redx management with new financing to support the RXC008 Phase 2 program.
The 5 Wall Street analysts covering Skye Bioscience, Inc. have a median 12-month price target of $4, with estimates ranging from $2 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Skye Bioscience, Inc., 3 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Skye Bioscience, Inc. 34 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Skye Bioscience, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +1328.6% from the last close, and Ticker Nerd's factor model ranks Skye Bioscience, Inc. 34 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Skye Bioscience, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SKYE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $20 over the next 12 months.
Skye Bioscience, Inc. returned -92.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Skye Bioscience is a clinical stage biopharmaceutical company based in San Diego, California, focused on developing novel medicines that modulate G-protein-coupled receptors, particularly targeting the endocannabinoid system to treat metabolic and neurological disorders. The company's lead program, nimacimab, is a negative allosteric modulating antibody designed to inhibit peripheral cannabinoid receptor 1, currently in Phase 2 development for obesity treatment.
The most recent item we track (Seeking Alpha, 14 Aug 2026): "Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript". Skye Bioscience, Inc. (SKYE) held an M&A call, and Seeking Alpha published the prepared remarks transcript from the event.
Skye Bioscience is a clinical stage biopharmaceutical company based in San Diego, California, focused on developing novel medicines that modulate G-protein-coupled receptors, particularly targeting the endocannabinoid system to treat metabolic and neurological disorders. The company's lead program, nimacimab, is a negative allosteric modulating antibody designed to inhibit peripheral cannabinoid receptor 1, currently in Phase 2 development for obesity treatment. In combination with existing weight loss therapies, nimacimab has demonstrated meaningful efficacy in clinical trials. The company's pipeline also includes SBI-100 Ophthalmic Emulsion, a cannabinoid receptor agonist in development for glaucoma and ocular hypertension. Skye's approach aims to address gaps in care left by current weight loss medications by targeting well-established biological pathways with strong human evidence. The company pursues partnerships with specialist life science investors and is advancing its clinical programs toward potential regulatory milestones in treating obesity and related metabolic conditions.
CEO Mr. Punit S. Dhillon B.A. · 12 employees · United States · https://skyebioscience.com